Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $75 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.
August 22, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Harmony Biosciences and maintained a $75 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Harmony Biosciences. The maintained price target of $75 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100